Study on the Relationship between the Use of Bisphosphonates for Antiosteoporosis and Vertebral Re-Fracture after Vertebroplasty

Table 2

Comparison of clinical data between the refracture group and the nonrefracture group.

Factors		Refracture group (n = 29)	Nonrefracture group (n = 121)	t/χ ^2
Gender	Male	6 (20.69)	26 (21.49)	0.009	0.925
	Female	23 (79.31)	95 (78.51)
Age (years)		68.10 ± 10.86	73.14 ± 7.54	3.586	0.001
BMI (kg/m^2)		21.92 ± 5.69	23.38 ± 3.71	1.698	0.092
BMD (T)		−3.97 ± 0.94	−3.52 ± 0.70	2.897	0.004
VAS (points)		7.82 ± 0.97	9.13 ± 0.71	8.273	0.001
Initial fracture site	≤T10	8 (27.58)	22 (18.18)	1.621	0.445
	T10∼L2	16 (55.17)	81 (66.94)
	L3∼L5	5 (17.24)	18 (14.88)
Postoperative antiosteoporosis therapy	Yes	12 (41.38)	88 (72.73)	10.345	0.001
	No	17 (58.62)	33 (27.27)